BASDAI Score Calculator
The BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) is a validated 6-question self-report instrument for measuring disease activity in ankylosing spondylitis (AS) and axial spondyloarthritis. Answer each question about your symptoms over the past week, and the calculator instantly computes your score on a 0 to 10 scale, with clinical interpretation and a guide to what your result means for treatment decisions.
Formula
Worked example
A patient scores: Fatigue 5, Axial pain 6, Peripheral joint pain 3, Enthesitis 4, Morning stiffness severity 7, Morning stiffness duration 1 hour (converted to 5). Morning stiffness average = (7 + 5) / 2 = 6. Sum = 5 + 6 + 3 + 4 + 6 = 24. BASDAI = 24 / 5 = 4.8, indicating high disease activity above the treatment threshold.
What is the BASDAI?
The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is the most widely used patient-reported outcome measure for assessing disease activity in ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA). It was developed in 1994 at the Royal National Hospital for Rheumatic Diseases in Bath, England, by a multidisciplinary team including rheumatologists, physiotherapists and occupational therapists. The tool covers five major symptom domains through six questions: fatigue, spinal pain, peripheral joint pain and swelling, enthesitis (inflammation at tendon and ligament attachment sites), and morning stiffness, which is assessed with two items covering severity and duration. Completion takes 30 seconds to 2 minutes, and validation studies have shown statistically significant reliability (p less than 0.001) and sensitivity to clinically meaningful change.
How the BASDAI formula works
Each of the six questions is scored on a 0 to 10 scale, where 0 means no symptoms and 10 means the worst imaginable. Morning stiffness is assessed twice (severity and duration) because both dimensions contribute independently to overall disease burden; the two scores are averaged before being included in the sum. The formula is: BASDAI = (Q1 + Q2 + Q3 + Q4 + ((Q5 + Q6) / 2)) / 5. The result is a single value from 0 to 10. The key clinical threshold is 4: scores at or above this level are internationally accepted to indicate suboptimal disease control. This threshold is used in the United Kingdom by NICE, in European guidelines by EULAR, and in North American ACR guidelines as one criterion for eligibility for biologic therapy.
Clinical use: treatment thresholds and monitoring
A BASDAI score of 4 or greater, combined with an inadequate response to two or more non-steroidal anti-inflammatory drugs (NSAIDs) over 4 weeks each, is a key gateway for biologic disease-modifying drugs. Anti-TNF agents (adalimumab, etanercept, infliximab, certolizumab, golimumab) and anti-IL-17 agents (secukinumab, ixekizumab) are approved for this indication and consistently reduce BASDAI scores. A 50% improvement, or a 2-unit absolute reduction, from baseline is often used to define a meaningful treatment response. In practice, rheumatologists combine the BASDAI with objective measures including C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), spinal MRI findings, and the BASFI (Bath Ankylosing Spondylitis Functional Index) to build a complete clinical picture. One important limitation is that patients with advanced, "burned out" disease may have low BASDAI scores despite severe structural damage, because active inflammation has been replaced by fibrosis.
BASDAI vs other AS outcome measures
Several complementary instruments are used alongside BASDAI. The ASDAS (Ankylosing Spondylitis Disease Activity Score) combines three BASDAI questions with CRP or ESR, making it a composite of patient-reported and laboratory data; it is increasingly favoured in clinical trials for that reason. The BASFI (Bath Ankylosing Spondylitis Functional Index) measures physical function rather than disease activity, with cut-offs linked to the ability to carry out daily tasks. The BASG (Bath Ankylosing Spondylitis Global score) assesses the patient's overall wellbeing. The BASMI (Bath AS Metrology Index) quantifies spinal mobility with five physical measurements. Together these tools allow clinicians to separate active inflammation (BASDAI, ASDAS) from the functional and structural consequences of longstanding disease (BASFI, BASMI).
BASDAI score interpretation
| BASDAI score | Disease activity | Typical clinical action |
|---|---|---|
| 0 - 1.9 | Remission / low | Continue current therapy; monitor every 6 months |
| 2.0 - 3.9 | Moderate | Optimise NSAIDs; reassess in 3-6 months |
| 4.0 - 5.9 | High (threshold) | Consider biologic therapy (anti-TNF / anti-IL-17) |
| 6.0 - 10 | Very high | Urgent therapy review; biologic escalation indicated |
Clinically accepted bands used in international spondyloarthritis treatment guidelines. A score of 4 is the key threshold recognised by NICE, EULAR and ACR guidelines.
Frequently asked questions
What does a BASDAI score of 4 mean?
A score of 4 is the internationally recognised threshold for suboptimal disease control in ankylosing spondylitis. UK (NICE), European (EULAR) and North American (ACR) guidelines all use this cut-off as one of the criteria for considering a switch to biologic therapy, particularly anti-TNF or anti-IL-17 agents, when NSAIDs have not provided adequate relief. A score below 4 suggests the disease is reasonably controlled with current treatment.
How is morning stiffness scored differently from the other questions?
Morning stiffness is the only symptom assessed by two questions: severity (Q5, rated 0-10) and duration (Q6, rated as a time range converted to a 0-10 equivalent). Because both dimensions measure the same underlying symptom domain, their scores are averaged before being included in the overall formula. This prevents morning stiffness from contributing double the weight of the other four symptom areas.
Can I use the BASDAI to monitor my response to treatment?
Yes, and this is one of its primary purposes. A reduction of 50% from your pre-treatment baseline score, or an absolute improvement of 2 or more points, is widely used to define a clinically meaningful response. Repeating the assessment every 3 to 6 months, or at each rheumatology appointment, gives your care team a reliable track record of how your disease is behaving over time.
Is a low BASDAI score always reassuring?
Not always. Patients with advanced or "burned out" AS may score well on the BASDAI despite significant structural damage, because the active inflammatory phase has subsided. In these cases, CRP, ESR and MRI findings are particularly important to assess the full picture. The BASDAI reflects current symptom burden rather than cumulative joint damage.
What is the difference between BASDAI and ASDAS?
BASDAI is a pure patient-reported measure: it uses only the answers to the six questions and needs no laboratory tests. The ASDAS (Ankylosing Spondylitis Disease Activity Score) combines three of those same questions with either CRP or ESR, giving a composite score that blends subjective symptoms with objective inflammation. ASDAS is increasingly used in clinical trials because the lab value reduces the influence of subjective reporting, but BASDAI remains practical in clinic because it requires no blood test.
Does BASDAI apply to non-radiographic axial spondyloarthritis (nr-axSpA)?
Yes. Although BASDAI was originally developed for ankylosing spondylitis (the radiographic form), it is now routinely used for the full axial spondyloarthritis spectrum, including nr-axSpA where structural changes on X-ray are absent but MRI may show bone marrow oedema. The same clinical threshold of 4 applies.
Sources
- Garrett S et al. (1994). A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. Journal of Rheumatology.
- van der Heijde D et al. (2017). ASAS/EULAR recommendations for the management of ankylosing spondylitis. Annals of the Rheumatic Diseases.